Navigation Links
Max Neeman International ISO 14155: 2011 Certified for Medical Device Trials

RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2011 /PRNewswire/ -- Max Neeman announces the grant of ISO 14155:2011 certificate; the only Indian CRO and one of only a few global CROs to be certified for design, conduct, recording and reporting of clinical investigations carried out in human subjects to assess the safety or performance of medical devices for regulatory purposes.


Max Neeman has formed an experienced team of medical device experts specializing in carrying out Cardiac, CNS, Ophthalmology and various other device therapeutic trials and ISO 14155 certification establishes standards to harmonize these trials ensuring safety, effectiveness, performance and quality. The company is part of the 'Max India Group' also consisting of Max Healthcare, which owns and manages a leading cardiovascular institute among its 13 hospitals.

The ISO 14155:2011 certification Max Neeman has achieved, specifies general requirements intended to protect the rights, safety and well-being of human subjects, ensure the scientific conduct of the clinical investigation and the credibility of the results, define the responsibilities of the sponsor and principal investigator, and assist sponsors, investigators, ethics committees, regulatory authorities and other bodies involved in the conformity assessment of medical devices.

With India's device market currently being valued at US $1.7 Billion and projected to grow at the rate of 23% annually, India is fast emerging as a destination of choice for medical device development and conducting device trials.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is also an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President USA for more information at +1.919.424.3345 /

SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
6. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
7. Max Neeman Develops Innovative Approach for Rare Disease Studies
8. Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
Post Your Comments:
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 ... nieuwe aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie ... ) --> ... (Photo: ) ... Medisch Centrum (LUMC) blijkt ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational ... it is so important to this key industry segment, Regis Technologies has decided to ... on December 4th at 11am EST. , Federal law does not allow new drugs ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of critical importance to the medical schools of the future. To reach an ... suite at the 2015 ChangeMedEd conference in Chicago, organized by the American Medical ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... their strategic partnership at the Radiological Society of North America (RSNA) 2015 ... global providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership ...
(Date:11/30/2015)... Wylie, TX (PRWEB) , ... November 30, 2015 , ... Bayco Products, Inc today announced ... only $11.95 each. Available in a choice of three different colors; red ( NSP-1632 ), ... can each run up to 18 hours in constant-on mode, or 27 hours in blinking ...
(Date:11/29/2015)... FL (PRWEB) , ... November 30, 2015 , ... The Cyber Monday deal is a ... It is the right time to get gifts for the skin care lover in your ... top filled with serums . This year, the 3 serums are staples: Collagen, Retinol and ...
Breaking Medicine News(10 mins):